# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001213900-25-113845
**Filing Date:** 2025-11
**Character Count:** 5781
**Document Hash:** 729bc3384bdb2badefff8e7284bf044e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-113845.hdr.sgml**: 20251124

**ACCESSION NUMBER**: 0001213900-25-113845

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251124

**FILED AS OF DATE**: 20251124

**DATE AS OF CHANGE**: 20251124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 251509576

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 24, 2025**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. [333-251073](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm), [333-248980](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) and [333-228671](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)) and our Registration Statements on Form F-3 (Files No. [333-274816](http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm), [333-251647](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm), [333-231417](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) and [333-250076](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm))**

**ALTERITY THERAPEUTICS LIMITED**

**(a development stage enterprise)**

The following exhibits are submitted:

99.1 [Final Director's Interest Notice - Meltzer](ea026689501ex99-1_alterity.htm)

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| By: | /s/ Julian Babarczy |
|  | Julian Babarczy |
|  | Chairman |

---

Date: November 24, 2025

## Exhibit 99.1

**Exhibit 99.1**

---

| |
|:---|
| **Appendix 3Z** |
| **Final Director's Interest Notice** |

---

Rule 3.19A.3

**Appendix 3Z**

**Final Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/9/2001.

---

| | |
|:---|:---|
| **Name of entity** | Alterity Therapeutics Limited |
| **ABN** | 37 080 699 065 |

---

We (the entity) give ASX the following information under listing rule 3.19.A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

---

| | |
|:---|:---|
| **Name of director** | Brian Meltzer |
| **Date of last notice** | 17 September 2025 |
| **Date that director ceased to be director** | 21 November 2025 |

---

**Part 1 - Director's relevant interests in securities of which the director is the registered holder**

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

**Number & class of securities<br>** <br> 9,415,584 - FULLY PAID ORDINARY SHARES<br> 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01<br> 757,576 - LISTED OPT EXP 26/02/2027 @ $0.028<br> 30,000,000 - UNLISTED OPT EXP 30/12/2027 @ $0.01

**Part 2 - Director's relevant interests in securities of which the director is not the registered holder**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

---

| | |
|:---|:---|
| **Name of holder & nature of interest** | **Number & class of Securities** |
| *Note: Provide details of the circumstances giving rise to the relevant interest.* |  |
| BT PORTFOLIO SERVICES (SMSF) | 326,666 - FULLY PAID ORDINARY SHARES |

---

**Part 3 - Director's interests in contracts**

---

| | |
|:---|:---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **No. and class of securities to which interest relates** | N/A |

---

+ See chapter 19 for defined terms. <br>11/03/2002 Appendix 3Z Page 1